101. Miller AD, Ball AM, Bookstaver PB, Dornblaser EK, Bennett CL.

Epileptogenic potential of carbapenem agents:

mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy. 2011;31(4):408-423.
doi:10.1592/phco.31.4.408 [PubMed 21449629]

102. Moehring R, Anderson DJ. Gram-negative bacillary bacteremia in adults. Post TW, ed. UpToDate. Waltham, MA:
UpToDate Inc. http://www.uptodate.com. Accessed December 10, 2019a.

103. Moehring R, Sarubbi C. Prolonged infusions of beta-lactam antibiotics. Post TW, ed. UpToDate. Waltham, MA:
UpToDate Inc. http://www.uptodate.com. Accessed September 13, 2019b.

104. Mohr JF 3rd. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial
infections. Clin Infect Dis. 2008;47(suppl 1):S41-51. doi:10.1086/590065 [PubMed 18713049]

105. Morgado F, Santiago L, Gonçalo M. Safe use of imipenem after delayed hypersensitivity to meropenem-value of
patch tests. Contact Dermatitis. 2020;82(3):190-191. doi:10.1111/cod.13435 [PubMed 31742726]

106. Munoz-Gomez S, Gran A, Cunha BA. Meropenem delirium: a previously unrecognized neurologic side effect. J
Chemother. 2015;27(2):120-121. doi:10.1179/1973947814Y.0000000179 [PubMed 24571247]

107. National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. Published
September 3, 2014. Accessed November 19, 2020. https://www.nice.org.uk/guidance/cg183

108. Naeije G, Lorent S, Vincent JL, Legros B. Continuous epileptiform discharges in patients treated with cefepime or
meropenem. Arch Neurol. 2011;68(10):1303-1307. doi:10.1001/archneurol.2011.204 [PubMed 21987544]

109. Nichols KR, Knoderer CA, Jackson NG, Manaloor JJ, Christenson JC. Success with extended-infusion meropenem
after recurrence of baclofen pump-related achromobacter xylosoxidans meningitis in an adolescent. J Pharm
Pract. 2015;28(4):430-433. doi:10.1177/0897190015585757 [PubMed 26033796]

110. Noguerado-Mellado B, Pinto Fernández C, Pineda-Pineda R, Martínez Lezcano P, Álvarez-Perea A, De Barrio

Fernández M. Cross-reactivity between carbapenems: two case reports. J Allergy Clin Immunol Pract.
2014;2(6):816-817. doi:10.1016/j.jaip.2014.06.015 [PubMed 25439383]

111. Odio CM, Puig JR, Feris JM, et al. Prospective, Randomized, Investigator-Blinded Study of the Efficacy and Safety
of Meropenem vs. Cefotaxime Therapy in Bacterial Meningitis in Children. Meropenem Meningitis Study Group.
Pediatr Infect Dis J. 1999;18(7):581-590. [PubMed 10440432]

112. Ohata Y, Tomita Y, Nakayama M, Tamura K, Tanigawara Y. Optimal treatment schedule of meropenem for adult
patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis. J Infect Chemother.
2011;17(6):831-841. doi: 10.1007/s10156-011-0271-9. [PubMed 21773752]

113. Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: clinical
practice guideline by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(1):e1-e25. doi:
10.1093/cid/cis803. [PubMed 23223583]
114. Osmon DR, Tande AJ. Osteomyelitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.
http://www.uptodate.com. Accessed December 10, 2019.

115. Padari H, Metsvaht T, Kõrgvee LT, et al. Short versus long infusion of meropenem in very-low-birth-weight
neonates. Antimicrob Agents Chemother. 2012;56(9):4760-4764. doi:10.1128/AAC.00655-12 [PubMed 22733063]

116. Pai MP, Cojutti P, Pea F. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in
overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose
optimization for the treatment of severe gram-negative bacterial infections. ClinPharmacokinet. 2015;54(9):933-
941. doi:10.1007/s40262-015-0266-2 [PubMed 25850987]

117. Paquet P, Jacob E, Damas P, Piérard GE. Recurrent fatal drug-induced toxic epidermal necrolysis (Lyell's
syndrome) after putative beta-lactam cross-reactivity: case report and scrutiny of antibiotic imputability. Crit
Care Med. 2002;30(11):2580-2583. doi:10.1097/00003246-200211000-00029 [PubMed 12441773]

118. Patel PR, Cook SE. Stability of meropenem in intravenous solutions. Am J Health Syst Pharm. 1997;54(4):412-421.
[PubMed 9043564]

119. Pemberton JH. Acute colonic diverticulitis: medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate
Inc. http://www.uptodate.com. Accessed December 11, 2019.

120. Pettit RS, Neu N, Cies JJ, et al. Population pharmacokinetics of meropenem administered as a prolonged infusion
in children with cystic fibrosis. J Antimicrob Chemother. 2016;71(1):189-195. doi:10.1093/jac/dkv289 [PubMed
26416780]

121. Prados-Castaño M, Piñero-Saavedra M, Leguísamo-Milla S, Ortega-Camarero M, Vega-Rioja A. DRESS syndrome

induced by meropenem. Allergol Immunopathol (Madr). 2015;43(2):233-235. doi:10.1016/j.aller.2013.12.004
[PubMed 24731770]

122. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of
sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304-377. doi:10.1007/s00134-017-4683-6 [PubMed
28101605]

123. Romano A, Gaeta F, Valluzzi RL, Caruso C, Rumi G, Bousquet PJ. IgE-mediated hypersensitivity to cephalosporins:
cross-reactivity and tolerability of penicillins, monobactams, and carbapenems. J Allergy Clin Immunol.
2010;126(5):994-999. doi:10.1016/j.jaci.2010.06.052 [PubMed 20888035]

124. Romano A, Viola M, Guéant-Rodriguez RM, Gaeta F, Valluzzi R, Guéant JL. Brief communication: tolerability of
meropenem in patients with IgE-mediated hypersensitivity to penicillins. Ann Intern Med. 2007;146(4):266-269.
doi:10.7326/0003-4819-146-4-200702200-00005 [PubMed 17310050]

125. Rubino CM, Bhavnani SM, Loutit JS, Lohse B, Dudley MN, Griffith DC. Single-dose pharmacokinetics and safety of
meropenem-vaborbactam in subjects with chronic renal impairment. Antimicrob Agents Chemother.
2018;62(3):e02103-17. doi:10.1128/AAC.02103-17 [PubMed 29311069]
126. Sameed M, Nwaiser C, Bhandari P, Schmalzle SA. Meropenem-induced Stevens-Johnson syndrome/toxic
epidermal necrolysis in a patient with known type IV penicillin hypersensitivity. BMJ Case Rep.
2019;12(8):e230144. doi:10.1136/bcr-2019-230144 [PubMed 31434673]

127. Sartelli M, Catena F, Abu-Zidan FM, et al. Management of intra-abdominal infections: recommendations by the
WSES 2016 consensus conference. World J Emerg Surg. 2017;12:22. doi: 10.1186/s13017-017-0132-7. [PubMed
28484510]

128. Sauberan JB, Bradley JS, Blumer J, Stellwagen LM. Transmission of meropenem in breast milk. Pediatr Infect Dis J.
2012;31(8):832-834. [PubMed 22544050]

129. Schmidt GA, Mandel J. Evaluation and management of suspected sepsis and septic shock in adults. Post TW, ed.
UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 10, 2019.

130. Sexton DJ, Sampson JH. Intracranial epidural abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.
http://www.uptodate.com. Accessed September 13, 2019a.

131. Sexton DJ, Sampson JH. Spinal epidural abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.
http://www.uptodate.com. Accessed September 13, 2019b.

132. Seyler L, Cotton F, Taccone FS, et al. Recommended β-lactam regimens are inadequate in septic patients treated
with continuous renal replacement therapy. Crit Care. 2011;15(3):R137. doi:10.1186/cc10257 [PubMed 21649882]

133. Shabaan AE, Nour I, Elsayed Eldegla H, Nasef N, Shouman B, Abdel-Hady H. Conventional versus prolonged
infusion of meropenem in neonates with gram-negative late-onset sepsis: a randomized controlled trial. Pediatr
Infect Dis J. 2017;36(4):358-363. doi:10.1097/INF.0000000000001445 [PubMed 27918382]

134. Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for
the diagnosis and management of infectious diarrhea. Clin Infect Dis. 2017;65(12):e45-e80.
doi:10.1093/cid/cix669 [PubMed 29053792]

135. Simon RH. Cystic fibrosis: treatment of acute pulmonary exacerbations. Post TW, ed. UpToDate. Waltham, MA:
UpToDate Inc. http://www.uptodate.com. Accessed December 10, 2019.

136. Sjövall F, Alobaid AS, Wallis SC, Perner A, Lipman J, Roberts JA. Maximally effective dosing regimens of
meropenem in patients with septic shock. J Antimicrob Chemother. 2018;73(1):191-198. doi: 10.1093/jac/dkx330.
[PubMed 28961812]

137. Smith PB, Cohen-Wolkowiez M, Castro LM, et al. Population pharmacokinetics of meropenem in plasma and
cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatr Infect Dis J.
2011;30(10):844-849. [PubMed 21829139]

138. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections
in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America
 [published correction appears in Clin Infect Dis. 2010;50(12):1695]. Clin Infect Dis. 2010;50(2):133-164. [PubMed
20034345]

139. Southwick FS. Treatment and prognosis of bacterial brain abscess. Post TW, ed. UpToDate. Waltham, MA:
UpToDate Inc. http://www.uptodate.com. Accessed February 11, 2020.

140. Spina Silva T, Dal-Prá Ducci R, Zorzetto FP, Braatz VL, de Paola L, Kowacs PA. Meropenem-induced myoclonus: a
case report. Seizure. 2014;23(10):912-914. doi:10.1016/j.seizure.2014.06.017 [PubMed 25066813]

141. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft
tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52.
doi: 10.1093/cid/ciu296. [PubMed 24947530]

142. Tamatsukuri T, Ohbayashi M, Kohyama N, et al. The exploration of population pharmacokinetic model for
meropenem in augmented renal clearance and investigation of optimum setting of dose. J Infect Chemother.
2018;24(10):834-840. doi:10.1016/j.jiac.2018.07.007 [PubMed 30087007]

143. Tegeder I, Neumann F, Bremer F, Brune K, Lötsch J, Geisslinger G. Pharmacokinetics of meropenem in critically ill
patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther.
1999;65(1):50-57. doi:10.1016/S0009-9236(99)70121-9 [PubMed 9951430]

144. Thalhammer F, Schenk P, Burgmann H, et al. Single-dose pharmacokinetics of meropenem during continuous
venovenous hemofiltration. Antimicrob Agents Chemother. 1998;42(9):2417-2420. [PubMed 9736573]

145. Tröger U, Drust A, Martens-Lobenhoffer J, Tanev I, Braun-Dullaeus RC, Bode-Böger SM. Decreased meropenem
levels in intensive care unit patients with augmented renal clearance: benefit of therapeutic drug monitoring. Int
J Antimicrob Agents. 2012;40(4):370-372. doi:10.1016/j.ijantimicag.2012.05.010 [PubMed 22795654]

146. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving
continuous renal replacement therapy. Clin Infect Dis. 2005;41(8):1159-1166. [PubMed 16163635]

147. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin
Infect Dis. 2004;39(9):1267-1284. [PubMed 15494903]

148. Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines
for healthcare-associated ventriculitis and meningitis. Clin Infect Dis. 2017;64(6):e34-e65.doi:10.1093/cid/ciw861
[PubMed 28203777]

149. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial
dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000
[PubMed 20000886]

150. Ulldemolins M, Soy D, Llaurado-Serra M, et al. Meropenem population pharmacokinetics in critically ill patients
with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.
Antimicrob Agents Chemother. 2015;59(9):5520-5528. doi:10.1128/AAC.00712-15 [PubMed 26124172]
151. van den Anker JN, Pokorna P, Kinzig-Schippers M, et al. Meropenem pharmacokinetics in the newborn.
Antimicrob Agents Chemother. 2009;53(9):3871-3879. [PubMed 19581463]

152. Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. Clostridium difficile infection following systemic antibiotic
administration in randomised controlled trials: a systematic review and meta-analysis. Int J Antimicrob Agents.
2016;48(1):1-10. doi:10.1016/j.ijantimicag.2016.03.008 [PubMed 27216385]

153. Venugopalan V, Manigaba K, Borgert SJ, Cope J, Peloquin CA, Klinker KP. Training a drug to do new tricks: insights
on stability of meropenem administered as a continuous infusion. Microbiol Insights.
2018;11:1178636118804549. doi:10.1177/1178636118804549 [PubMed 30349291]

154. Vollmer CM, Zakko SF, Afdhal NH. Treatment of acute calculous cholecystitis. Post TW, ed. UpToDate. Waltham,
MA: UpToDate Inc. http://www.uptodate.com. Accessed December 11, 2019.

155. Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-onset
Clostridium difficile infections in a large healthcare system. Clin Infect Dis. 2018;66(12):1957-1959.
doi:10.1093/cid/cix1112 [PubMed 29272341]

156. Weintrob AC, Sexton DJ. Clinical manifestations, diagnosis, and management of diabetic infections of the lower
extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November
24, 2020.

157. Wingard JR. Treatment of neutropenic fever syndromes in adults with hematologic malignancies and
hematopoietic cell transplant recipients (high-risk patients). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.
http://www.uptodate.com. Accessed December 10, 2020.

158. Wong Kee Song L-M, Marcon NE. Neutropenic enterocolitis (typhlitis). Post TW, ed. UpToDate. Waltham, MA:
UpToDate Inc. http://www.uptodate.com. Accessed December 10, 2020.

159. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the
eleventh WHO model list of essential drugs. 2002. Available at
http://www.who.int/maternal_child_adolescent/documents/55732/en/

160. Yahav D, Franceschini E, Koppel F, et al; Bacteremia Duration Study Group. Seven versus fourteen days of
antibiotic therapy for gram-negative bacteremia: a non-inferiority randomized controlled trial [published online
ahead of print December 11, 2018]. Clin Infect Dis. doi: 10.1093/cid/ciy1054. [PubMed 30535100]

161. Yildirim I, Aytac S, Ceyhan M, et al. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as
empirical treatment of febrile neutropenia in childhood hematological malignancies. Pediatr Hematol Oncol.
2008;25(4):291-299. [PubMed 18484473]10.1080/08880010802016847

162. Yoshida M, Matsuda H, Furuya K. Successful prognosis of brain abscess during pregnancy. J Reprod Infertil.
2013;14(3):152-155. [PubMed 24163800]
163. Yu Z, Pang X, Wu X, Shan C, Jiang S. Clinical outcomes of prolonged infusion (extended infusion or continuous
infusion) versus intermittent bolus of meropenem in severe infection: a meta-analysis. PLoS One.
2018;13(7):e0201667. doi: 10.1371/journal.pone.0201667. [PubMed 30059536]

164. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007;67(7):1027-1052.
doi:10.2165/00003495-200767070-00006. [PubMed 17488146]

165. Zobell JT, Ferdinand C, Young DC. Continuous infusion meropenem and ticarcillin-clavulanate in pediatric cystic
fibrosis patients. Pediatr Pulmonol. 2014;49(3):302-306. doi:10.1002/ppul.22820 [PubMed 23775821]

166. Zobell JT, Young DC, Waters CD, et al. Optimización de antibióticos antipseudomonas para las exacerbaciones
pulmonares de la fibrosis quística: I. aztreonam y carbapenémicos. Pediatr Pulmonol. 2012; 47 (12): 1147-1158.
doi: 10.1002 / ppul.22655. [PubMed 22911974 ]

Tema 9613 Versión 294.0